Strengthening the Generic Drugs Supply Chain

In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain. The report details various areas where the national generic supply chain is weak and various ways that it can be strengthened.

Natalie de Graaf, VP and GM of data, AI, and machine learning and solutions for health and national security at the API Innovation Center, spoke with Pharmaceutical Executive about the report’s findings. The conversation touched on the following points:

• What data-driven approach is the API Innovation Center using to assess supply chain fragility?
• How can the US work with allies to reduce foreign drug dependency?
• What are the most fragile drug classes in the US supply chain?